Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

801
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
801
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Cancer Vaccines01:30

Cancer Vaccines

600
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
600
Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

HemaSphere·2026
Same author

The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population-Based Analysis.

American journal of hematology·2026
Same author

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.

Blood cancer journal·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Blood cancer journal·2026
Same author

Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma.

Cancer·2026

Related Experiment Video

Updated: Nov 5, 2025

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

667

Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift.

Meera Mohan1, Parameswaran Hari1, Binod Dhakal1

  • 1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.

JCO Oncology Practice
|May 18, 2021
PubMed
Summary

Immune-based therapies, including daratumumab and T-cell treatments, show promise for multiple myeloma (MM). These approaches aim to re-engage the immune system to fight cancer, offering new hope for patients with limited options.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K

Related Experiment Videos

Last Updated: Nov 5, 2025

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

667
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma (MM) is a complex, largely incurable blood cancer.
  • Tumor-induced immunosuppression hinders effective treatment.
  • Recent advances focus on leveraging the immune system against MM.

Purpose of the Study:

  • To review the promise of immunologic approaches in treating multiple myeloma.
  • To highlight the transformative potential of immune-based therapies in MM management.

Main Methods:

  • Review of current literature on immune-based therapies for MM.
  • Analysis of clinical trial data for agents like daratumumab, bispecific antibodies, and CAR T-cell therapies.
  • Discussion of ongoing research and future directions.

Main Results:

  • Anti-CD38 antibody daratumumab demonstrates significant efficacy, particularly in combination therapies.
  • T-cell engaging therapies, including bispecific antibodies and CAR T-cells, show promising antimyeloma effects.
  • Early clinical trials indicate deeper, durable responses in heavily pretreated MM patients.

Conclusions:

  • Immunologic approaches represent a significant paradigm shift in multiple myeloma treatment.
  • These therapies offer new hope and potentially transformative outcomes for MM patients.
  • Ongoing trials are investigating various immune-based strategies across different MM stages.